YAP1 and non-small cell lung carcinoma: In a cohort analysis of 64 EGFR mutant NSCLC patients (62 had common mutations L858R and exon 19 deletion; the other two had the uncommon mutations L861Q and G719X) treated with first-line EGFR-TKIs, patients with a high level of expression of STAT3 or YAP1 had a worse progression-free survival following EGFR-TKI therapy.